Pharmaceutical giant Wyeth has shot down arguments by rival Merck Sharp & Dohme that its Prevnar 13 vaccine lacked inventiveness, saying during the closing submissions of a high-stakes patent trial that up until it developed the top-selling shot scientists thought there was a “ceiling” of 11 types of pneumococcal bacteria that could be included in a single vaccine.
A judge has dismissed a class action against Powercor over a bushfire in the Gazette area of South West Victoria on St. Patrick’s Day 2018, calling the allegations “fanciful”.
A judge won’t defer the opt-out notice in a shareholder class action against GetSwift pending the High Court’s decision on a special leave application to revive a competing class action, saying the sooner the case settles the better.
The Australian Securities and Investments Commission will likely appeal a ruling that two Westpac units did not provide personal financial advice as part of a campaign encouraging customers to roll over external superannuation accounts.
A Coles manager who sexually harassed and bullied young female employees by touching them and asking them to friend him on Facebook was fired by the supermarket giant for a valid reason, the workplace umpire has found.
Fairfax Media is moving forward with a lawsuit against Network Ten over the alleged infringement of its “Boss” trade mark, even after the TV broadcaster agreed to stop using the name.
Maurice Blackburn has dropped its investigation of a possible class action on behalf of owners of units in Sydney’s faulty Opal Tower, but Corrs Chambers Westgarth is still pursuing a potential case.
Law firms Maurice Blackburn and Phi Finney McDonald have stepped back from a proposed consolidation of their class actions against the Commonwealth Bank of Australia and want to run their own cases again, but now with “harmonised” pleadings.
A judge has recommended another shareholder vote over Boart Longyear’s plan to move to Canada, saying a letter by a minority shareholder warning the move could imperil a possible class action against the distressed mining services company was misleading and affected the integrity of the vote.
Claims by Wyeth that its patented Prevnar 13 pneumococcal vaccine was inventive because other pharmaceutical giants had failed in developing similar vaccines are based on “hearsay and speculation,” Merck Sharp & Dohme told the court during closing submissions in the high-stakes trial over the world’s best-selling vaccine.